Structure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low – Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $19.11 and last traded at $19.16, with a volume of 42940 shares. The stock had previously closed at $19.94.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GPCR. Stifel Nicolaus began coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

The firm has a 50-day moving average of $24.19 and a 200-day moving average of $31.22. The firm has a market capitalization of $1.13 billion, a P/E ratio of -26.72 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently added to or reduced their stakes in GPCR. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the period. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $34,000. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $40,000. Finally, Virtus ETF Advisers LLC increased its stake in shares of Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after buying an additional 455 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.